X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs NOVARTIS - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA NOVARTIS SANOFI INDIA/
NOVARTIS
 
P/E (TTM) x 39.9 328.0 12.2% View Chart
P/BV x 8.6 36.4 23.7% View Chart
Dividend Yield % 1.0 1.3 83.4%  

Financials

 SANOFI INDIA   NOVARTIS
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
NOVARTIS
Mar-18
SANOFI INDIA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs4,560758 601.6%   
Low Rs4,400579 759.9%   
Sales per share (Unadj.) Rs1,028.5228.4 450.3%  
Earnings per share (Unadj.) Rs129.031.7 406.3%  
Cash flow per share (Unadj.) Rs186.032.8 567.6%  
Dividends per share (Unadj.) Rs68.0010.00 680.0%  
Dividend yield (eoy) %1.51.5 101.5%  
Book value per share (Unadj.) Rs753.6297.1 253.6%  
Shares outstanding (eoy) m23.0324.69 93.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.42.9 148.8%   
Avg P/E ratio x34.721.1 164.9%  
P/CF ratio (eoy) x24.120.4 118.1%  
Price / Book Value ratio x5.92.2 264.2%  
Dividend payout %52.731.5 167.3%   
Avg Mkt Cap Rs m103,17416,505 625.1%   
No. of employees `0003.60.7 542.4%   
Total wages/salary Rs m3,5921,445 248.5%   
Avg. sales/employee Rs Th6,537.78,441.3 77.4%   
Avg. wages/employee Rs Th991.42,163.6 45.8%   
Avg. net profit/employee Rs Th819.81,173.1 69.9%   
INCOME DATA
Net Sales Rs m23,6865,639 420.1%  
Other income Rs m7081,718 41.2%   
Total revenues Rs m24,3947,357 331.6%   
Gross profit Rs m5,281-63 -8,449.6%  
Depreciation Rs m1,31325 5,189.7%   
Interest Rs m1555 27.1%   
Profit before tax Rs m4,6611,575 295.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,691792 213.6%   
Profit after tax Rs m2,970784 379.0%  
Gross profit margin %22.3-1.1 -2,011.6%  
Effective tax rate %36.350.3 72.2%   
Net profit margin %12.513.9 90.2%  
BALANCE SHEET DATA
Current assets Rs m15,6739,522 164.6%   
Current liabilities Rs m6,6783,296 202.6%   
Net working cap to sales %38.0110.4 34.4%  
Current ratio x2.32.9 81.2%  
Inventory Days Days7637 207.5%  
Debtors Days Days2228 78.5%  
Net fixed assets Rs m8,09846 17,604.3%   
Share capital Rs m230123 186.6%   
"Free" reserves Rs m17,0887,213 236.9%   
Net worth Rs m17,3567,336 236.6%   
Long term debt Rs m00-   
Total assets Rs m25,40011,105 228.7%  
Interest coverage x311.729.5 1,057.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.5 183.7%   
Return on assets %11.87.6 155.6%  
Return on equity %17.110.7 160.2%  
Return on capital %26.922.2 121.2%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627NA-   
Fx inflow Rs m7,14561 11,790.4%   
Fx outflow Rs m6,8463,630 188.6%   
Net fx Rs m299-3,570 -8.4%   
CASH FLOW
From Operations Rs m3,2261,610 200.4%  
From Investments Rs m-1,555687 -226.3%  
From Financial Activity Rs m-1,818-2,677 67.9%  
Net Cashflow Rs m-147-380 38.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 60.4 75.0 80.5%  
Indian inst/Mut Fund % 14.4 2.0 720.0%  
FIIs % 14.6 1.6 912.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 21.5 48.8%  
Shareholders   15,184 41,647 36.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   PLETHICO PHARMA  BIOCON LTD  J.B.CHEMICALS  ALKEM LABORATORIES  DIVIS LABORATORIES  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 21, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - FULFORD INDIA COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS